Descripción del proyecto
Una innovadora plataforma «in silico» para el diseño de matrices vasculares biorreabsorbibles farmacoactivas
La aterosclerosis supone una importante carga para las personas en Europa y en todo el mundo. Por ello, urge encontrar soluciones innovadoras que mejoren el tratamiento y la calidad de vida de los pacientes. El equipo del proyecto InSilc, financiado con fondos europeos, está desarrollando una plataforma de ensayos clínicos «in silico» para ayudar a investigadores, cardiólogos y expertos de la industria biomédica a diseñar, desarrollar y evaluar matrices vasculares biorreabsorbibles (BVS, por sus siglas en inglés) farmacoactivas. Para lograr este objetivo, se emplearán modelos computacionales avanzados y amplios conocimientos biomédicos y biológicos para simular el rendimiento de la implantación de la endoprótesis en anatomías cardiovasculares específicas de cada paciente. La introducción de la plataforma InSilc aportará mejoras significativas en el enfoque del tratamiento de implantación de endoprótesis, lo que se traducirá en una reducción de los costes directos e indirectos de prestación de asistencia sanitaria.
Objetivo
The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.
Ámbito científico
- medical and health sciencesclinical medicineangiologyvascular diseases
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsfluid dynamics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinephysiology
- natural sciencesmathematicsapplied mathematicsstatistics and probability
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2017-CNECT-2
Régimen de financiación
RIA - Research and Innovation actionCoordinador
70013 Irakleio
Grecia